Frequently Asked Questions about Guardant Health, Inc. (GH)

Name: Guardant Health, Inc. (GH) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Guardant Health, Inc. (GH) do?

Accepted Answer

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an...

Question 2

Is Guardant Health, Inc. (GH) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of GH reveals an Altman Z-Score of 1.72 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.98B most recent), help investors decide if GH fits their risk profile.

Question 3

What is the current P/E ratio for GH?

Accepted Answer

As of the latest trading session, Guardant Health, Inc. (GH) has a trailing P/E ratio of -26.94.

Question 4

Who is the CEO of Guardant Health, Inc.?

Accepted Answer

The current Chief Executive Officer of Guardant Health, Inc. is Helmy Eltoukhy.

Question 5

What was GH's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Guardant Health, Inc. reported annual revenues of $0.98B (2025), $0.74B (2024), $0.56B (2023), $0.45B (2022), $0.37B (2021) respectively.

Question 6

Does GH pay a dividend?

Accepted Answer

Guardant Health, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does GH have?

Accepted Answer

In its latest reporting period, Guardant Health, Inc. generated $-0.23B in Free Cash Flow against a total debt load of $1.68B.

Question 8

What is the Price-to-Book (P/B) ratio of Guardant Health, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Guardant Health, Inc. (GH) is currently -112.93.

Question 9

What is the Price-to-Sales (P/S) ratio of GH?

Accepted Answer

Based on trailing twelve-month data, Guardant Health, Inc. (GH) trades at a Price-to-Sales (P/S) ratio of 11.64.

Question 10

What is Guardant Health, Inc.'s Return on Equity (ROE)?

Accepted Answer

Guardant Health, Inc. (GH) has a Return on Equity (ROE) of 164.85%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	982M	633M	-436.3M	-416.3M	-3.32
2024-12	739M	449.2M	-443.6M	-436.4M	-3.56
2023-12	563.9M	336.9M	-564.7M	-479.4M	-4.28
2022-12	449.5M	293.2M	-544.4M	-654.6M	-6.41
2021-12	373.7M	250.7M	-411M	-405.7M	-3.80

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	982M	633M	-436.3M	-416.3M	-3.32
2024-12	739M	449.2M	-443.6M	-436.4M	-3.56
2023-12	563.9M	336.9M	-564.7M	-479.4M	-4.28
2022-12	449.5M	293.2M	-544.4M	-654.6M	-6.41
2021-12	373.7M	250.7M	-411M	-405.7M	-3.80